StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Research analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Trading Down 3.2 %

Shares of Minerva Neurosciences stock opened at $2.11 on Tuesday. Minerva Neurosciences has a 12-month low of $2.03 and a 12-month high of $13.49. The firm’s 50 day simple moving average is $2.21 and its two-hundred day simple moving average is $2.57. The firm has a market capitalization of $14.75 million, a price-to-earnings ratio of -4.80 and a beta of 0.11.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.